<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurol Neuroimmunol Neuroinflamm</journal-id><journal-id journal-id-type="iso-abbrev">Neurol Neuroimmunol Neuroinflamm</journal-id><journal-id journal-id-type="hwp">nnn</journal-id><journal-id journal-id-type="publisher-id">NEURIMMINFL</journal-id><journal-title-group><journal-title>Neurology® Neuroimmunology &amp; Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">2332-7812</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28680915</article-id><article-id pub-id-type="pmc">5489138</article-id><article-id pub-id-type="publisher-id">NEURIMMINFL2016011262</article-id><article-id pub-id-type="doi">10.1212/NXI.0000000000000358</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>19</subject><subject>41</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Comparative utility of disability progression measures in PPMS</article-title><subtitle>Analysis of the PROMiSe data set</subtitle></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Koch</surname><given-names>Marcus W.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1. Roche pharmaceuticals 2. Biogen</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>1. Genzyme Sanofi 2. Biogen</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>1. Teva pharmaceuticals</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1. Alberta Innovated Health Solutions</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Cutter</surname><given-names>Gary R.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Participation of Data and Safety Monitoring Committees: AMO Pharmaceuticals, Apotek, Gilead Pharmaceuticals, Horizon Pharmaceuticals, Modigenetech/Prolor, Merck, Merck/Pfizer, Opko Biologics, Sanofi-Aventis, Reata Pharmaceuticals, Receptos/Celgene, Teva pharmaceuticals, NHLBI (Protocol Review Committee), NICHD (OPRU oversight committee).</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(1) Consortium of MS Centers, speaker honoraria; (2) Teva, Speaker honoraria</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Multiple Sclerosis, Editorial Board, 2010-present (2) JASN, 2013- present, statistical consulting reviewer (3) Alzheimers &amp; Dementia: Translational Research &amp; Clinical Interventions</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>(1) Employed by the University of Alabama at Birmingham; (2) President of Pythagoras, Inc. a private consulting company located in Birmingham AL.</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Atara Biotherapeutics, Bioeq GmBH, Cerespir Inc, Consortium of MS Centers (grant), Genzyme, Genentech, Innate Therapeutics, Jannsen Pharmaceuticals, Klein-Buendel Incorporated, Medimmune, Medday, Nivalis, Novartis, Opexa Therapeutics, Roche, Savara Inc., Somahlution, Teva pharmaceuticals, Transparency Life Sciences, TG Therapeutics</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other activities:</title><list-item><p>(1) NARCOMS MS Patient Registry funded by CMSC</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>No direct grants, but work on studies funded to the Consortium of MS Centers subcontracted for analysis of NARCOMS Registry.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>ACTIVE U01 NS 042685 (Cutter) 09/23/2005 ? 08/31/2015 NIH/NINDS Thymectomy Plus Prednisone vs. Prednisone Alone in NonThymomatous Myasthenia Gravis This multinational clinical trial aims to assess the utility of thymectomy in treating nonthymomatous Myasthenia Gravis patients comparing surgery plus medications versus medications alone. P30-AI 027767 (Saag, M.) 06/01/2014 ? 05/31/2019 NIH/NIAID UAB Center for Aids Research This CFAR is organized as a partnership between the University of Alabama at Birmingham and the Southern Research Institute. The primary purpose of this partnership is to generate interdisciplinary AIDS research efforts. This Center is responsible for planning, evaluating, managing and documenting a broad array of research activities within two institutions. Particular emphasis is placed upon linking clinical and basic science studies through the use of shared facilities and to translate as quickly as possible fundamental knowledge about AIDS and its related disorders into clinical treatment and prevention programs. U01-HL 119242 (Cutter) 09/01/2014 ? 05/31/2020 NIH/NHLBI Chronic Hypertension and Pregnancy (CHAP): Data Coordinating Center We propose a large pragmatic multi-center randomized trial of pregnant women with mild chronic hypertension to evaluate the benefits and harms of antihypertensive therapy to a goal &lt;140/90 mmHg (as recommended for the general population in the US) compared with ACOG's current policy of expectant management of mild chronic hypertension in pregnancy. The trial will be conducted in 12 experienced research-oriented Ob/Gyn departments (including 25 clinical sites) in the United States. The monitoring plan will include a pre-specified option to increase the planned sample size of 4700 women after interim evaluation by an independent Data Safety and Monitoring Board. R01 HD 064729 (Tita) 04/01/2010 ? 07/31/2015 NIH/NICHD Caesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) Trial A multicenter randomized trial to determine the efficacy and safety of a modified (extended-spectrum) antibiotic prophylaxis strategy at cesarean delivery to reduce surgical site infections. R01 AG 021927 (Marson) 07/01/2010 ? 06/30/2015 NIH/NIA Functional Change in Mild Cognitive Impairment (COINS) This R01 project investigates longitudinal change in higher order functional abilities in patients with MCI, and develops predictor models for clinical progression and conversion from MCI to dementia. No number assigned (Cutter) 01/01/2004 ? 12/31/2015 Consortium of MS Centers (CMSC) North American Research Consortium on Multiple Sclerosis (NARCOMS) The goals of this project are to facilitate a confidential way for patients to supply valuable information to researchers about their course of disease that may lead to more effective treatments and care. W81XWH-12-1-0155 (Korf) 05/15/2012 ? 05/14/2017 U.S. Department of Defense NEUTOFIBOMATOSIS CLINICAL CONSORTIUM AWARD This is a cooperative study group that is focusing on multiple trials in NF. The role of the operations center is both as the data center and the overall coordinating of the study group. U01NS45719 (Lublin) 06/01/2004 ? 11/30/2015 NIH/NINDS CombiRx Statistical and Data Management Center A Phase III, multi-center, double-blind, randomized study comparing the combined use of Interferon Beta-1a and Glatiramer Acetate to either agent alone in patients with relapsing remitting multiple sclerosis. 140305 (Greenberg) 09/01/2013 ? 08/31/2016 Patient Centered Outcomes Research Institute Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate (CAPTURE) U34 AR062891 (K. Saag) 04/15/2013 ? 03/31/2015 NIH/NIAMS Effectiveness of DiscontinuinG BisphosphonatEs Study (EDGE) Planning grant for a Pragmatic Clinical Trial (PCT), ?Effectiveness of DiscontinuinG bisphosphonatEs (EDGE) Study?, a ?real world? effectiveness trial of an initially estimated 4,100 patients randomized to continuation or discontinuation of prior alendronate therapy. P30DK079337 (Agarwal) 09/20/13 ? 07/31/18 NIH/NIDDK UAB/UCSD O?Brien Core Center for Acute Kidney Injury Research In summary, these cores and the outstanding cohort of investigators assembled for this center will provide unique expertise that is critical for innovative and productive research in AKI. With its Extended Research Base that includes both clinical and basic investigators, this O'Brien center will accelerate the translation of new investigative insights towards novel therapies for patients with AKI. RSTFD0000541263 (Cutter) 09/01/13 ? 08/31/17 Children?s Hospital (Boston) Early Biomarkers of Autism Spectrum Disorders in Infants with Tuberous Sclerosis MG Registry (Cutter) 01/01/14-present (annually) MGFA This is new registry (1.5 years old) that is a patient registry of Myasthenia Gravis Patients based solely on patient reported outcomes tracking their disease over time. CBD Trial (Cutter) 04/01/2014 ? 9/30/2015 State of Alabama The data management center for the effectiveness of cannabidiol (CBD) oil for the treatment of seizures and epilepsy.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) Consortium of MS Centers (2) Myasthenia Gravis Foundation of America, grant for MG Registry</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>Pythagoras, Inc. Sub S Corporation - President.</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>Galderma Litigation (acne case) reviewed statistical data</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Giovannoni</surname><given-names>Gavin</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Speaker honoraria: (1)Biogen-Idec (2) Genzyme (3) GW Pharma (4) Merck-Serono (5) Novartis (6) Roche (7) Teva</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Multiple Sclerosis and Related Disorders, Editor since 2011</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>(1) Novartis (2) Teva</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Genzyme 2012-2014 Merck 2012-2014</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Uitdehaag</surname><given-names>Bernard M.J.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Novartis, Merck Serono, Biogen Idec, TEVA, Sanofi Genzyme and Roche</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Wolinsky</surname><given-names>Jerry S.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Compensation for service on steering committees or data monitoring boards for Clene Nanomedicine, Forward Pharma, MedDay, Novartis Pharmaceuticals, Roche/Genentech, and Sanofi/Genzyme.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(1) Honoraria were provided from ACTRIMS, AcademicCME, CMSC, PRIME, WebMD, University of Kansas and University of Maryland for CME activities. (2) Travel support was provided from ECTRIMS as invited faculty several meetings, and ACTRIMS as Keynote Speaker for the New Orleans meeting.</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Multiple Sclerosis Journal, Sage, Editorial Board, 1994 - 2017 (2) Multiple Sclerosis and Related Diseases, Elsevier, Section Editor, 2011 - present</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Reimbursement for services as consultant to AbbVie, Acetilon, Alkermes, Bayer HealthCare, Celgene, Forward Pharma, EMD Serono, Genzyme, Novartis, Roche, Taketa, and Teva.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>National Institutes of Health, NS078244-01A1 (Co- investigator), 2012 - 2017</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License fee payments, Technology or Inventions:</title><list-item><p>(1) Royalties are received for monoclonal antibodies out-licensed through the University of Texas Health Science Center at Houston to Millipore (Chemicon International) Corporation since 1993.</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Mat D.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Teva Pharmaceuticals, 3 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>Teva Pharmaceuticals, 3 years</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Steinerman</surname><given-names>Joshua R.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Data Safety Monitoring Board for an NIH-sponsored study</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>(1) Teva Pharmaceuticals</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1) Click Therapeutics</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>(1) Teva Pharmaceuticals (2) Click Therapeutics</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Knappertz</surname><given-names>Volker</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Employee at Teva Pharmaceuticals Industries</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other activities:</title><list-item><p>Stock and options in TEVA. Stock and Options in Knopp Biosciences, Pittsburgh PA</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Employee of TEVA.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>Stock and options in TEVA. Stock and Options in Knopp Biosciences, Pittsburgh PA</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the Departments of Clinical Neurosciences and Community Health Sciences (M.W.K.), University of Calgary, Alberta, Canada; University of Alabama at Birmingham (G.R.C.); Barts and The London School of Medicine and Dentistry (G.G.), London, UK; Vrije Universiteit University Medical Center (B.M.J.U.), Amsterdam, The Netherlands; McGovern Medical School (J.S.W.), Department of Neurology, University of Texas Health Science Center at Houston; Teva Pharmaceutical Industries (M.D.D., J.R.S., V.K.), Frazer, PA; and Heinrich-Heine Universität Düsseldorf (V.K.), Germany.</aff></contrib-group><author-notes><corresp>Correspondence to Dr. Koch: <email>abormes@hcg-int.com</email></corresp><fn fn-type="financial-disclosure"><p>Funding information and disclosures are provided at the end of the article. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXI.0000000000000358">Neurology.org/nn</ext-link> for full disclosure forms. The Article Processing Charge was funded by the authors.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>5</month><year>2017</year></pub-date><volume>4</volume><issue>4</issue><elocation-id>e358</elocation-id><history><date date-type="received"><day>03</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEURIMMINFL2016011262.pdf"></self-uri><abstract><sec><title><offsets xml_i="33888" xml_f="33898" txt_i="11" txt_f="21">Objective:</offsets></title><p><offsets xml_i="33909" xml_f="34044" txt_i="22" txt_f="157">To assess the comparative utility of disability progression measures in primary progressive MS (PPMS) using the PROMiSe trial data set.</offsets></p></sec><sec><title><offsets xml_i="34066" xml_f="34074" txt_i="159" txt_f="167">Methods:</offsets></title><p><offsets xml_i="34085" xml_f="34592" txt_i="168" txt_f="675">Data for patients randomized to placebo (n = 316) in the PROMiSe trial were included in this analysis. Disability was assessed using change in single (Expanded Disability Status Scale [EDSS], timed 25-foot walk [T25FW], and 9-hole peg test [9HPT]) and composite disability measures (EDSS/T25FW, EDSS/9HPT, and EDSS/T25FW/9HPT). Cumulative and cross-sectional unconfirmed disability progression (UDP) and confirmed disability progression (CDP; sustained for 3 months) rates were assessed at 12 and 24 months.</offsets></p></sec><sec><title><offsets xml_i="34614" xml_f="34622" txt_i="677" txt_f="685">Results:</offsets></title><p><offsets xml_i="34633" xml_f="35122" txt_i="686" txt_f="1175">CDP rates defined by a ≥20% increase in T25FW were higher than those defined by EDSS score at 12 and 24 months. CDP rates defined by T25FW or EDSS score were higher than those defined by 9HPT score. The 3-part composite measure was associated with more CDP events (41.4% and 63.9% of patients at 12 and 24 months, respectively) than the 2-part measure (EDSS/T25FW [38.5% and 59.5%, respectively]) and any single measure. Cumulative UDP and CDP rates were higher than cross-sectional rates.</offsets></p></sec><sec><title><offsets xml_i="35144" xml_f="35156" txt_i="1177" txt_f="1189">Conclusions:</offsets></title><p><offsets xml_i="35167" xml_f="35554" txt_i="1190" txt_f="1577">The T25FW or composite measures of disability may be more sensitive to disability progression in patients with PPMS and should be considered as the primary endpoint for future studies of new therapies. CDP may be the preferred measure in classic randomized controlled trials in which cumulative disability progression rates are evaluated; UDP may be feasible for cross-sectional studies.</offsets></p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><offsets xml_i="35736" xml_f="35878" txt_i="1586" txt_f="1728">Patients with primary progressive MS (PPMS) represent 10%–15% of patients with MS and suffer the highest neurodegeneration-related disability.</offsets><sup><xref rid="R1" ref-type="bibr"><offsets xml_i="35914" xml_f="35915" txt_i="1728" txt_f="1729">1</offsets></xref><xref ref-type="bibr" rid="R2"><offsets xml_i="35953" xml_f="35954" txt_i="1729" txt_f="1730">–</offsets></xref><xref rid="R4" ref-type="bibr"><offsets xml_i="35992" xml_f="35993" txt_i="1730" txt_f="1731">4</offsets></xref></sup><offsets xml_i="36006" xml_f="36169" txt_i="1731" txt_f="1894"> There are currently no approved treatments to ameliorate disease progression in PPMS, and there are several barriers to developing therapeutics in progressive MS.</offsets><sup><xref rid="R2" ref-type="bibr"><offsets xml_i="36205" xml_f="36206" txt_i="1894" txt_f="1895">2</offsets></xref><offsets xml_i="36213" xml_f="36214" txt_i="1895" txt_f="1896">,</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="36245" xml_f="36246" txt_i="1896" txt_f="1897">5</offsets></xref></sup><offsets xml_i="36259" xml_f="36432" txt_i="1897" txt_f="2070"> Specifically, individual disability measures may lack the sensitivity required to reveal all cases of disease progression within the defined time frame of a clinical trial.</offsets><sup><xref rid="R6" ref-type="bibr"><offsets xml_i="36468" xml_f="36469" txt_i="2070" txt_f="2071">6</offsets></xref></sup></p><p><offsets xml_i="36489" xml_f="36637" txt_i="2072" txt_f="2220">The Expanded Disability Status Scale (EDSS) remains the typical outcome measure in PPMS trials. However, it has been widely recognized as inadequate</offsets><sup><xref rid="R7" ref-type="bibr"><offsets xml_i="36673" xml_f="36674" txt_i="2220" txt_f="2221">7</offsets></xref></sup><offsets xml_i="36687" xml_f="36740" txt_i="2221" txt_f="2274"> and is associated with several important weaknesses.</offsets><sup><xref rid="R3" ref-type="bibr"><offsets xml_i="36776" xml_f="36777" txt_i="2274" txt_f="2275">3</offsets></xref></sup><offsets xml_i="36790" xml_f="36908" txt_i="2275" txt_f="2393"> Other widely used measures of disability in MS include the timed 25-foot walk (T25FW) and the 9-hole peg test (9HPT).</offsets><sup><xref rid="R8" ref-type="bibr"><offsets xml_i="36944" xml_f="36945" txt_i="2393" txt_f="2394">8</offsets></xref><offsets xml_i="36952" xml_f="36953" txt_i="2394" txt_f="2395">,</offsets><xref rid="R9" ref-type="bibr"><offsets xml_i="36984" xml_f="36985" txt_i="2395" txt_f="2396">9</offsets></xref></sup><offsets xml_i="36998" xml_f="37314" txt_i="2396" txt_f="2712"> Recent studies have suggested that a combined disability measure that incorporates scoring from multiple instruments—for example, using T25FW, 9HPT, and EDSS—may be associated with more progression events among patients with PPMS, and thus higher reported event rates than achieved with any single instrument alone.</offsets><sup><xref rid="R9" ref-type="bibr"><offsets xml_i="37350" xml_f="37351" txt_i="2712" txt_f="2713">9</offsets></xref><offsets xml_i="37358" xml_f="37359" txt_i="2713" txt_f="2714">,</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="37391" xml_f="37393" txt_i="2714" txt_f="2716">10</offsets></xref></sup></p><p><offsets xml_i="37413" xml_f="37654" txt_i="2717" txt_f="2958">The PROMiSe study represents one of the best and largest (N = 943) data sources on patients with PPMS and offers a unique opportunity to assess the value of different functional measures of disability progression in a clinical trial setting.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="37691" xml_f="37693" txt_i="2958" txt_f="2960">11</offsets></xref></sup><offsets xml_i="37706" xml_f="37967" txt_i="2960" txt_f="3221"> We report here the results of an analysis of the PROMiSe data set undertaken to better understand the utility of the different measures of disability progression—EDSS, T25FW, and 9HPT alone and in combinations—and to inform the design of future trials in PPMS.</offsets></p><sec sec-type="methods" id="s1"><title><offsets xml_i="38010" xml_f="38017" txt_i="3222" txt_f="3229">METHODS</offsets></title><sec id="s1-1"><title><offsets xml_i="38047" xml_f="38112" txt_i="3230" txt_f="3295">Standard protocol approvals, registrations, and patient consents.</offsets></title><p><offsets xml_i="38123" xml_f="38454" txt_i="3296" txt_f="3627">Participating study sites in each individual country locally ensured all necessary regulatory approvals (e.g., institutional review boards/institutional ethics committees) in accordance with local regulations, including local data protection regulations used in the original collection of the data for this secondary data analysis.</offsets></p></sec><sec id="s1-2"><title><offsets xml_i="38486" xml_f="38499" txt_i="3629" txt_f="3642">Study design.</offsets></title><p><offsets xml_i="38510" xml_f="38674" txt_i="3643" txt_f="3807">The data set for this analysis was derived from the PROMiSe study, a randomized, double-blind, placebo-controlled clinical trial with a planned duration of 3 years.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="38711" xml_f="38713" txt_i="3807" txt_f="3809">11</offsets></xref></sup><offsets xml_i="38726" xml_f="38788" txt_i="3809" txt_f="3871"> The design of the PROMiSe study has been reported previously.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="38825" xml_f="38827" txt_i="3871" txt_f="3873">11</offsets></xref></sup><offsets xml_i="38840" xml_f="39073" txt_i="3873" txt_f="4106"> In summary, patients who took part in the PROMiSe study (N = 943) were randomized in a 2:1 ratio to receive glatiramer acetate (GA) 20 mg once daily (n = 627) or identical-appearing placebo (n = 316) by daily subcutaneous injection.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="39110" xml_f="39112" txt_i="4106" txt_f="4108">11</offsets></xref></sup><offsets xml_i="39125" xml_f="39414" txt_i="4108" txt_f="4397"> The primary endpoint was time to confirmed disability progression (CDP), with CDP being defined as a change of ≥1 point on the EDSS sustained for 3 months in patients with a baseline EDSS score of 3.0–5.0, or a change of ≥0.5 points for 3 months in those with a baseline score of 5.5–6.5.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="39451" xml_f="39453" txt_i="4397" txt_f="4399">11</offsets></xref></sup><offsets xml_i="39466" xml_f="39633" txt_i="4399" txt_f="4566"> Patients also completed the MS Functional Composite (MSFC) evaluation, a 3-part test including the T25FW and 9HPT and the Paced Auditory Serial Addition Test (PASAT).</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="39670" xml_f="39672" txt_i="4566" txt_f="4568">11</offsets></xref></sup></p></sec><sec id="s1-3"><title><offsets xml_i="39717" xml_f="39726" txt_i="4570" txt_f="4579">Patients.</offsets></title><p><offsets xml_i="39737" xml_f="40150" txt_i="4580" txt_f="4993">Patients eligible to participate in the PROMiSe study were aged between 30 and 65 years, with an EDSS score of 3.0–6.5, investigator-confirmed PPMS, and progressive symptoms including myelopathy for ≥6 months before screening. Additional eligibility criteria included evidence of pyramidal damage on neurologic examination, including a pyramidal functional system score ≥2, and evidence of multilevel CNS disease.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="40187" xml_f="40189" txt_i="4993" txt_f="4995">11</offsets></xref></sup><offsets xml_i="40202" xml_f="40482" txt_i="4995" txt_f="5272"> Patients with any history of MS relapse, those with lymphopenia &lt;3,000 cells/mL, and those who had used an interferon-β drug, immunosuppressant, immunomodulating agent, corticosteroid, or investigational drug within 3 months of study initiation were not eligible to take part.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="40519" xml_f="40521" txt_i="5272" txt_f="5274">11</offsets></xref></sup></p><p><offsets xml_i="40541" xml_f="40798" txt_i="5275" txt_f="5532">Only data for patients randomized to placebo in the PROMiSe trial were included in this analysis in order to compare clinical measures in patients with PPMS for whom the natural course of the disease was not potentially affected by exposure to GA treatment.</offsets></p></sec><sec id="s1-4"><title><offsets xml_i="40830" xml_f="40850" txt_i="5534" txt_f="5554">Outcome evaluations.</offsets></title><p><offsets xml_i="40861" xml_f="41438" txt_i="5555" txt_f="6132">Disability was assessed using change in single (EDSS, T25FW, and 9HPT) and composite disability measures. Combination endpoints were defined as progression by EDSS or T25FW, 9HPT or T25FW, or by EDSS or T25FW or 9HPT. The PASAT was not included in this analysis of the PROMiSe database because of the potential for practice effects occurring from repeated administration. Moreover, the test may have limited measurement reliability, is sometimes difficult to administer, has been used less frequently in recent MS trials, and is not anticipated to be featured in future trials.</offsets></p><p><offsets xml_i="41445" xml_f="41623" txt_i="6133" txt_f="6311">As per the PROMiSe study protocol, worsening of the EDSS was defined as a change from baseline of ≥1 point (for baseline EDSS 3.0–5.0) or ≥0.5 points (for baseline EDSS 5.5–6.5).</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="41660" xml_f="41662" txt_i="6311" txt_f="6313">11</offsets></xref></sup><offsets xml_i="41675" xml_f="41878" txt_i="6313" txt_f="6516"> Worsening of the T25FW was defined as an increase of ≥20% compared with baseline or as the inability to complete the T25FW after baseline due to worsening disability (increase of EDSS to 7.0 or higher).</offsets><sup><xref rid="R12" ref-type="bibr"><offsets xml_i="41915" xml_f="41917" txt_i="6516" txt_f="6518">12</offsets></xref></sup><offsets xml_i="41930" xml_f="42193" txt_i="6518" txt_f="6781"> Worsening of the 9HPT was defined as an increase of ≥20% compared with baseline (calculated as the average across 4 trials: 2 in the dominant hand and 2 in the nondominant hand) or as the inability to complete the 9HPT after baseline due to worsening disability.</offsets><sup><xref rid="R12" ref-type="bibr"><offsets xml_i="42230" xml_f="42232" txt_i="6781" txt_f="6783">12</offsets></xref></sup><offsets xml_i="42245" xml_f="42349" txt_i="6783" txt_f="6887"> For each measure, rates of unconfirmed disability progression (UDP) and of 3-month CDP were determined.</offsets></p><p><offsets xml_i="42356" xml_f="42822" txt_i="6888" txt_f="7354">Two trial methodologies were evaluated: cumulative and cross-sectional. The cumulative approach describes the design of the PROMiSe trial and similar large-scale randomized clinical trials, with outcome measurement every 3 months and disability progression at any time point during follow-up contributing to an overall CDP proportion. The cross-sectional approach describes the design for simple, straightforward investigator-initiated trials such as futility trials</offsets><sup><xref rid="R13" ref-type="bibr"><offsets xml_i="42859" xml_f="42861" txt_i="7354" txt_f="7356">13</offsets></xref></sup><offsets xml_i="42874" xml_f="42932" txt_i="7356" txt_f="7414"> and observational studies on PPMS disability progression.</offsets><sup><xref rid="R10" ref-type="bibr"><offsets xml_i="42969" xml_f="42971" txt_i="7414" txt_f="7416">10</offsets></xref></sup><offsets xml_i="42984" xml_f="43331" txt_i="7416" txt_f="7763"> In this case, the measurement at one follow-up time point (e.g., 12 months) is compared with the baseline measurement. This analysis is restricted to patients in the PROMiSe trial receiving placebo in order to compare clinical measures in patients with PPMS for whom the natural course of the disease was not affected by exposure to GA treatment.</offsets></p></sec><sec id="s1-5"><title><offsets xml_i="43363" xml_f="43384" txt_i="7765" txt_f="7786">Statistical analyses.</offsets></title><p><offsets xml_i="43395" xml_f="44430" txt_i="7787" txt_f="8822">Cumulative progression rates were estimated using the Kaplan-Meier methodology. For summaries by month, 1 month was defined as 28 days. For confirmed disability events, patients who experienced a worsening event in the measure of interest that could not be confirmed due to the patient's discontinuation from the trial prior to the confirmation visit were censored at the time of the worsening. Other patients who did not experience the progression event were censored at their last day in the study. Cross-sectional progression rates were determined by comparing baseline and follow-up disability measures. Patients missing any of the 3 disability measures at baseline, the time point of interest, or the corresponding confirmation assessment were excluded from the analysis. The relative percentage contribution of each disability measure to disease progression rates observed for the combined EDSS or T25FW or 9HPT measure was derived by determining the number of individual patients progressing on 1, 2, or all 3 outcomes measures.</offsets></p></sec></sec><sec sec-type="results" id="s2"><title><offsets xml_i="44485" xml_f="44492" txt_i="8825" txt_f="8832">RESULTS</offsets></title><p><offsets xml_i="44503" xml_f="45000" txt_i="8833" txt_f="9330">A total of 316 patients were assigned to receive placebo in the PROMiSe study; 314 of these patients had a postbaseline EDSS assessment, and these patients constituted the population for the cumulative analyses presented here. Of these, 272 patients were included in the 12-month cross-sectional analysis, and 214 patients constitute the population for the 24-month cross-sectional analysis. Baseline demographic and clinical characteristics for the 314 patients who received placebo are shown in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="45032" xml_f="45039" txt_i="9330" txt_f="9337">table 1</offsets></xref><offsets xml_i="45046" xml_f="45047" txt_i="9337" txt_f="9338">.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="45084" xml_f="45086" txt_i="9338" txt_f="9340">11</offsets></xref></sup><offsets xml_i="45099" xml_f="45253" txt_i="9340" txt_f="9494"> The baseline characteristics of the subgroup of patients assigned to receive placebo were consistent with those of the entire PROMiSe patient population.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="45290" xml_f="45292" txt_i="9494" txt_f="9496">11</offsets></xref></sup></p><table-wrap id="T1" orientation="portrait" position="float"><label><offsets xml_i="45376" xml_f="45383" txt_i="9497" txt_f="9504">Table 1</offsets></label><caption><p><offsets xml_i="45403" xml_f="45538" txt_i="9504" txt_f="9639">Baseline demographic and clinical characteristics of patients who took part in the PROMiSe trial and were randomized to receive placebo</offsets></p></caption><graphic xlink:href="NEURIMMINFL2016011262TT1"></graphic></table-wrap><p><xref ref-type="table" rid="T2"><offsets xml_i="45657" xml_f="45664" txt_i="9640" txt_f="9647">Table 2</offsets></xref><offsets xml_i="45671" xml_f="46796" txt_i="9647" txt_f="10772"> shows cumulative and cross-sectional UDP and CDP rates at 12 and 24 months. Among single measures, a ≥20% worsening in T25FW (T25FW 20%) was associated with the highest cumulative progression rates, followed by EDSS and then a ≥20% worsening in 9HPT (9HPT 20%) at both the 12- and 24-month time points. Among combined measures, the composite of all 3 individual measures (i.e., EDSS or T25FW 20% or 9HPT 20%) had the highest cumulative 3-month CDP rate at both 12 and 24 months (41.4% and 63.9%, respectively). Cross-sectional 3-month CDP rates were also highest for the composite of all 3 scores than for any single or dual combination of scores at both 12 and 24 months (37.5% and 57.5%, respectively). UDP proportions were consistently higher than CDP proportions for all measures, with a considerably greater difference between UDP and CDP in the cumulative incidence of the composite of all 3 individual measures (1 year: 63.8% and 41.4%, respectively; 2 years: 82.1% and 63.9%, respectively) compared with the cross-sectional proportions (1 year: 47.8% and 37.5%, respectively; 2 years: 57.5% and 52.8%, respectively).</offsets></p><table-wrap id="T2" orientation="portrait" position="float"><label><offsets xml_i="46867" xml_f="46874" txt_i="10773" txt_f="10780">Table 2</offsets></label><caption><p><offsets xml_i="46894" xml_f="46978" txt_i="10780" txt_f="10864">Cumulative and cross-sectional PROMiSe disease progression rates at 12 and 24 months</offsets></p></caption><graphic xlink:href="NEURIMMINFL2016011262TT2"></graphic></table-wrap><p><offsets xml_i="47065" xml_f="47193" txt_i="10865" txt_f="10993">The proportion of patients with UDP and 3-month CDP for each of the disability metrics over the course of the study is shown in </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="47223" xml_f="47231" txt_i="10993" txt_f="11001">figure 1</offsets></xref><offsets xml_i="47238" xml_f="47448" txt_i="11001" txt_f="11211"> for each study paradigm (cumulative and cross sectional). The T25FW 20%-alone values were closely aligned with those from the combined EDSS-or-T25FW 20% values at all time points over the course of the study (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="47480" xml_f="47487" txt_i="11211" txt_f="11218">table 3</offsets></xref><offsets xml_i="47494" xml_f="47496" txt_i="11218" txt_f="11220">).</offsets></p><fig id="F1" orientation="portrait" position="float"><label><offsets xml_i="47560" xml_f="47568" txt_i="11221" txt_f="11229">Figure 1</offsets></label><caption><title><offsets xml_i="47592" xml_f="47688" txt_i="11229" txt_f="11325">Comparison of cumulative and cross-sectional UDP and CDP rates for EDSS, T25FW 20%, and 9HPT 20%</offsets></title><p><offsets xml_i="47699" xml_f="47941" txt_i="11326" txt_f="11568">(A) EDSS rates. (B) T25FW 20% rates. (C) 9HPT 20% rates. 3M CDP = 3-month confirmed disability progression; 9HPT = 9-hole peg test; EDSS = Expanded Disability Status Scale; T25FW = timed 25-foot walk; UDP = unconfirmed disability progression.</offsets></p></caption><graphic xlink:href="NEURIMMINFL2016011262FF1"></graphic></fig><table-wrap id="T3" orientation="portrait" position="float"><label><offsets xml_i="48085" xml_f="48092" txt_i="11569" txt_f="11576">Table 3</offsets></label><caption><p><offsets xml_i="48112" xml_f="48174" txt_i="11576" txt_f="11638">Disease progression rates over the course of the PROMiSe study</offsets></p></caption><graphic xlink:href="NEURIMMINFL2016011262TT3"></graphic></table-wrap><p><offsets xml_i="48261" xml_f="48445" txt_i="11639" txt_f="11823">The relative contribution of each of the individual component measures—together and in different combinations—of a 3-part composite measure (EDSS or T25FW 20% or 9HPT 20%) is shown in </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="48475" xml_f="48483" txt_i="11823" txt_f="11831">figure 2</offsets></xref><offsets xml_i="48490" xml_f="48509" txt_i="11831" txt_f="11850"> and figure e-1 at </offsets><ext-link ext-link-type="uri" xlink:href="10.1212/NXI.0000000000000358"><offsets xml_i="48581" xml_f="48597" txt_i="11850" txt_f="11866">Neurology.org/nn</offsets></ext-link><offsets xml_i="48608" xml_f="49150" txt_i="11866" txt_f="12408">. T25FW 20% had the greatest contribution to the overall measure, followed by EDSS, and then 9HPT 20%. These figures support the notion that CDP as defined by T25FW identifies individuals as progressors that the other measures would not have been identified. In other words, a greater proportion of patients identified as progressors by T25FW were not identified as progressors by EDSS or 9HPT, as compared with the proportion of patients identified as progressors by EDSS who were not identified as progressors by T25FW or 9HPT (figure e-2).</offsets></p><fig id="F2" orientation="portrait" position="float"><label><offsets xml_i="49214" xml_f="49222" txt_i="12409" txt_f="12417">Figure 2</offsets></label><caption><title><offsets xml_i="49246" xml_f="49427" txt_i="12417" txt_f="12598">Contribution of individual clinical measures evaluating patient worsening at 24 months (cross-sectional 3-month CDP) within a 3-part combined measure (EDSS or T25FW 20% or 9HPT 20%)</offsets></title><p><offsets xml_i="49438" xml_f="49729" txt_i="12599" txt_f="12890">(A) Cumulative UDP. (B) Cumulative 3-month CDP. (C) Cross-sectional UDP. (D) Cross-sectional 3-month CDP. 3M CDP = 3-month confirmed disability progression; 9HPT = 9-hole peg test; EDSS = Expanded Disability Status Scale; T25FW = timed 25-foot walk; UDP = unconfirmed disability progression.</offsets></p></caption><graphic xlink:href="NEURIMMINFL2016011262FF2"></graphic></fig></sec><sec sec-type="discussion" id="s3"><title><offsets xml_i="49854" xml_f="49864" txt_i="12892" txt_f="12902">DISCUSSION</offsets></title><p><offsets xml_i="49875" xml_f="50586" txt_i="12903" txt_f="13614">The data presented here show that among patients with PPMS randomized to receive placebo in the PROMiSe study, T25FW 20% at 12 and 24 months was associated with higher rates of disability progression than EDSS, and both T25FW 20% and EDSS were associated with higher disability rates than 9HPT 20%. The 3-part combination measure (EDSS or T25FW 20% or 9HPT 20%) was associated with more 3-month CDP events (41.4% and 63.9% of patients as 12 and 24 months, respectively) than the 2-part measure (EDSS or T25FW 20% [38.5% and 59.5%, respectively]), and more progression events than any single measure (EDSS, 14.9% and 32.4%, respectively; T25FW, 33.5% and 52.0%, respectively; 9HPT, 8.4% and 18.0%, respectively).</offsets></p><p><offsets xml_i="50593" xml_f="50948" txt_i="13615" txt_f="13970">Minimal changes in the 9HPT 20% outcome were noted over the course of the PROMiSe trial. As such, this measure may be less suitable than EDSS and T25FW 20% when used alone; however, 9HPT may still have utility as part of a composite measure. Moreover, future studies should explore thresholds other than 20% worsening on performance measures such as 9HPT.</offsets></p><p><offsets xml_i="50955" xml_f="51825" txt_i="13971" txt_f="14841">A marked difference was noted between cumulative and cross-sectional progression rates, which may inform the design of PPMS trials. Cumulative progression rates were generally higher than cross-sectional rates, but more strikingly, there was a greater difference between unconfirmed and CDP using the cumulative approach. Based on our results, the normative approach to use CDP in classic randomized controlled trials is supported. Failure to confirm disability progression may have a neurobiological basis or may be due to measurement unreliability; it would be preferable to exclude these from pivotal trial analyses in both cases. For trials using the cross-sectional approach, measures of UDP may still be feasible. Such studies would be resource-sparing and less burdensome for participants, but would have acknowledged data sparsity and methodological limitations.</offsets></p><p><offsets xml_i="51832" xml_f="52078" txt_i="14842" txt_f="15088">The observations presented here add to a growing body of evidence that suggests that combining specific disability measurements may be more useful in the clinical trial setting for assessing progression in patients with PPMS than single measures.</offsets><sup><xref rid="R9" ref-type="bibr"><offsets xml_i="52114" xml_f="52115" txt_i="15088" txt_f="15089">9</offsets></xref><offsets xml_i="52122" xml_f="52123" txt_i="15089" txt_f="15090">,</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="52155" xml_f="52157" txt_i="15090" txt_f="15092">10</offsets></xref><offsets xml_i="52164" xml_f="52165" txt_i="15092" txt_f="15093">,</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="52197" xml_f="52199" txt_i="15093" txt_f="15095">14</offsets></xref><xref ref-type="bibr" rid="R15"><offsets xml_i="52238" xml_f="52239" txt_i="15095" txt_f="15096">–</offsets></xref><xref rid="R16" ref-type="bibr"><offsets xml_i="52278" xml_f="52280" txt_i="15096" txt_f="15098">16</offsets></xref></sup><offsets xml_i="52293" xml_f="52528" txt_i="15098" txt_f="15333"> In a retrospective database study of 181 patients with progressive MS (primary 47% of patients and secondary 53% of patients), combining change in T25FW with EDSS was significantly more predictive of patient prognosis than EDSS alone.</offsets><sup><xref rid="R15" ref-type="bibr"><offsets xml_i="52565" xml_f="52567" txt_i="15333" txt_f="15335">15</offsets></xref></sup><offsets xml_i="52580" xml_f="53142" txt_i="15335" txt_f="15897"> An earlier retrospective database study of 161 patients with PPMS found that when comparing single measures or 2-instrument combinations involving EDSS, T25FW, and 9HPT, T25FW/9HPT predicted the greatest number of progression events after 1 year (46% of patients progressed compared with 17%, 34%, and 20% for the individual measures, respectively), and the combination of T25FW/EDSS predicted the greatest number of progression events after the second year (57% of patients progressed compared with 32%, 46%, and 24% for the individual measures, respectively).</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="53179" xml_f="53181" txt_i="15897" txt_f="15899">11</offsets></xref></sup><offsets xml_i="53194" xml_f="53259" txt_i="15899" txt_f="15964"> An evaluation of data from the 96-week Olympus (rituximab) trial</offsets><sup><xref rid="R17" ref-type="bibr"><offsets xml_i="53296" xml_f="53298" txt_i="15964" txt_f="15966">17</offsets></xref></sup><offsets xml_i="53311" xml_f="53508" txt_i="15966" txt_f="16163"> in the 147 patients with PPMS randomized to placebo found that a combined measure consisting of EDSS/T25FW/9HPT was associated with more CDP events than did any single or dual combination measure.</offsets><sup><xref rid="R11" ref-type="bibr"><offsets xml_i="53545" xml_f="53547" txt_i="16163" txt_f="16165">11</offsets></xref></sup><offsets xml_i="53560" xml_f="53708" txt_i="16165" txt_f="16313"> Progression rates at 96 weeks were 61.9% and 54.8% for those patients with an initial confirmed progression event at 12 and 24 weeks, respectively.</offsets><sup><xref rid="R9" ref-type="bibr"><offsets xml_i="53744" xml_f="53745" txt_i="16313" txt_f="16314">9</offsets></xref></sup><offsets xml_i="53758" xml_f="53940" txt_i="16314" txt_f="16496"> Confirmed progression rates for EDSS alone were 38.5% and 30.4%; for T25FW alone the rates were 51.0% and 44.5%; and for the 9HPT alone the rates were 21.1% and 17.4%, respectively.</offsets><sup><xref rid="R9" ref-type="bibr"><offsets xml_i="53976" xml_f="53977" txt_i="16496" txt_f="16497">9</offsets></xref></sup><offsets xml_i="53990" xml_f="54371" txt_i="16497" txt_f="16878"> Most recently, the large, prospective INFORMS (fingolimod) study, comprising patients with PPMS treated for at least 3 years, reported that a composite of EDSS, T25FW, or 9HPT predicted more progression events (80.3% cumulative probability of CDP) than any of the individual components alone (EDSS 58.7%, T25FW 70.0%, and 9HPT 41.3% of patients) among those randomized to placebo.</offsets><sup><xref rid="R14" ref-type="bibr"><offsets xml_i="54408" xml_f="54410" txt_i="16878" txt_f="16880">14</offsets></xref></sup></p><p><offsets xml_i="54430" xml_f="55068" txt_i="16881" txt_f="17519">Although those previous published studies offer similar conclusions to this study regarding the relative utility of outcome measures, they differ in several important ways that distinguish them from our analysis of the PROMiSe data set. The retrospective database study included both primary and secondary progressive patients with MS, was primarily focused on outcomes of early vs late changes on clinical scales, included patients who were exposed to disease-modifying therapies (DMTs) during the course of the study, did not set a minimum disability criterion as per EDSS for study entry, and included less-frequent patient assessment.</offsets><sup><xref rid="R15" ref-type="bibr"><offsets xml_i="55105" xml_f="55107" txt_i="17519" txt_f="17521">15</offsets></xref></sup><offsets xml_i="55120" xml_f="55341" txt_i="17521" txt_f="17742"> Similarly, the earlier study likely included patients exposed to DMTs, while its entry criteria included an EDSS threshold score of 2.0–6.5, representing a less-disabled patient population than that of the PROMiSe study.</offsets><sup><xref rid="R10" ref-type="bibr"><offsets xml_i="55378" xml_f="55380" txt_i="17742" txt_f="17744">10</offsets></xref></sup><offsets xml_i="55393" xml_f="55617" txt_i="17744" txt_f="17968"> The same EDSS criteria applied to the Olympus study, whereas none of these 3 studies, nor the INFORMS study, compared confirmed with unconfirmed progression or offered a cross-sectional analysis of disease progression data.</offsets><sup><xref rid="R9" ref-type="bibr"><offsets xml_i="55653" xml_f="55654" txt_i="17968" txt_f="17969">9</offsets></xref><offsets xml_i="55661" xml_f="55662" txt_i="17969" txt_f="17970">,</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="55694" xml_f="55696" txt_i="17970" txt_f="17972">14</offsets></xref></sup></p><p><offsets xml_i="55716" xml_f="55836" txt_i="17973" txt_f="18093">Two other recently published studies address similar themes and arrive at compatible conclusions to those of this study.</offsets><sup><xref rid="R18" ref-type="bibr"><offsets xml_i="55873" xml_f="55875" txt_i="18093" txt_f="18095">18</offsets></xref><offsets xml_i="55882" xml_f="55883" txt_i="18095" txt_f="18096">,</offsets><xref rid="R19" ref-type="bibr"><offsets xml_i="55915" xml_f="55917" txt_i="18096" txt_f="18098">19</offsets></xref></sup><offsets xml_i="55930" xml_f="56046" txt_i="18098" txt_f="18214"> In one of these studies, however, the patient population consisted entirely of those with secondary progressive MS,</offsets><sup><xref rid="R18" ref-type="bibr"><offsets xml_i="56083" xml_f="56085" txt_i="18214" txt_f="18216">18</offsets></xref></sup><offsets xml_i="56098" xml_f="56460" txt_i="18216" txt_f="18578"> whereas the other had a lower EDSS inclusion threshold (1–7), allowed inclusion of patients who had been treated with DMTs as recently as 3 months prior to study entry, and was intended as a validation study of a novel disability score (CombiWISE); that scoring measure, in addition to EDSS, T25FW, and 9HPT, also includes the Scripps Neurological Rating Scale.</offsets><sup><xref rid="R19" ref-type="bibr"><offsets xml_i="56497" xml_f="56499" txt_i="18578" txt_f="18580">19</offsets></xref></sup><offsets xml_i="56512" xml_f="56659" txt_i="18580" txt_f="18727"> And, as with the previously noted studies, neither unconfirmed disease nor a cross-sectional analysis was included in the design of these studies.</offsets><sup><xref rid="R18" ref-type="bibr"><offsets xml_i="56696" xml_f="56698" txt_i="18727" txt_f="18729">18</offsets></xref><offsets xml_i="56705" xml_f="56706" txt_i="18729" txt_f="18730">,</offsets><xref rid="R19" ref-type="bibr"><offsets xml_i="56738" xml_f="56740" txt_i="18730" txt_f="18732">19</offsets></xref></sup><offsets xml_i="56753" xml_f="57119" txt_i="18732" txt_f="19098"> Thus, this study offers several unique features that make it a potentially valuable contribution to the literature, such as reflecting the untreated natural history of PPMS by including only patients receiving placebo, including patients with more severe disability, comparing confirmed and unconfirmed disease progression, and including a cross-sectional analysis.</offsets></p><p><offsets xml_i="57126" xml_f="57961" txt_i="19099" txt_f="19934">There is an unmet need for controlling disease progression in patients with PPMS. For these patients, individual measures of disease progression may limit the potential to assess the benefit of new agents to the extent that the composite measures have higher event rates. Based on the observations presented here and those from previous studies, future studies of agents for the treatment of PPMS may benefit from either using T25FW 20% as a single outcome measure or using T25FW 20% in combination with the EDSS as a primary efficacy endpoint rather than EDSS alone, particularly if higher event rates over shorter exposure periods are sought. It is largely unknown whether specific disability outcomes would differentially detect treatment effects or whether this would differ according to the mechanism of the treatment under study.</offsets></p></sec><offsets xml_i="57971" xml_f="57972" txt_i="19936" txt_f="19937">
</offsets><sec sec-type="supplementary-material"><offsets xml_i="58011" xml_f="58012" txt_i="19937" txt_f="19938">
</offsets><title><offsets xml_i="58019" xml_f="58041" txt_i="19938" txt_f="19960">Supplementary Material</offsets></title><offsets xml_i="58049" xml_f="58050" txt_i="19961" txt_f="19962">
</offsets><supplementary-material id="PMC_1" content-type="local-data"><offsets xml_i="58111" xml_f="58112" txt_i="19962" txt_f="19963">
</offsets><caption><offsets xml_i="58121" xml_f="58122" txt_i="19963" txt_f="19964">
</offsets><title><offsets xml_i="58129" xml_f="58144" txt_i="19964" txt_f="19979">Data Supplement</offsets></title><offsets xml_i="58152" xml_f="58153" txt_i="19980" txt_f="19981">
</offsets></caption><offsets xml_i="58163" xml_f="58164" txt_i="19981" txt_f="19982">
</offsets><media mimetype="text" mime-subtype="html" xlink:href="supp_4_4_e358__index.html"></media><offsets xml_i="58254" xml_f="58255" txt_i="19982" txt_f="19983">
</offsets><media xlink:role="associated-file" mimetype="text" mime-subtype="html" xlink:href="supp_4.4.e358_16-12-23_PPT_supplementary_fig_e1.pdf.html"></media><offsets xml_i="58405" xml_f="58406" txt_i="19983" txt_f="19984">
</offsets><media xlink:role="associated-file" mimetype="text" mime-subtype="html" xlink:href="supp_4.4.e358_16-12-23_PPT_supplementary_fig_e2.pdf.html"></media><offsets xml_i="58556" xml_f="58557" txt_i="19984" txt_f="19985">
</offsets></supplementary-material><offsets xml_i="58582" xml_f="58583" txt_i="19985" txt_f="19986">
</offsets></sec><offsets xml_i="58589" xml_f="58590" txt_i="19987" txt_f="19988">
</offsets></body><back><fn-group><fn fn-type="supplementary-material"><p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="10.1212/NXI.0000000000000358">Neurology.org/nn</ext-link></p></fn></fn-group><ack><title>ACKNOWLEDGMENT</title><p>The authors thank the patients, investigators, and site personnel involved with the PROMiSe study. Dr. Justin Potuzak provided editorial support at the express direction of the authors. He had no role in the design or conceptualization of the study, in analysis or interpretation of the data, or in revising the manuscript for intellectual content.</p></ack><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">Marcus W. Koch: conception of the study, data analysis, writing of the first draft, and revision of the manuscript. Gary R. Cutter: study/analysis review, manuscript review, and approval. Gavin Giovannoni: study/analysis design, manuscript review, and approval. Bernard M.J. Uitdehaag: study/analysis review, manuscript review, and approval. Jerry S. Wolinsky: overall conduct and image analysis of the original clinical trial, warehoused components of the trial data, early investigation of the database for clinical-biomarker correlations, evaluation plan and data review, and preparation of this manuscript. Mat D. Davis: study/analysis design, data analysis, manuscript preparation, review, and approval. Joshua R. Steinerman: study/analysis design, manuscript preparation, review, and approval. Volker Knappertz: study/analysis design, data analysis, manuscript preparation, review, and approval.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">This study was funded by Teva Pharmaceutical Industries.</p></sec><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">M.W. Koch served on the scientific advisory board for Roche and Biogen; received travel funding and/or speaker honoraria from Genzyme Sanofi and Biogen; and received research support from Teva and Alberta Innovated Health Solutions. G.R. Cutter served on the data and safety monitoring committees for AMO Pharmaceuticals, Apotek, Gilead, Horizon, Modigenetech/Prolor, Merck, Merck/Pfizer, OPKO Biologics, Sanofi-Aventis, Reata, Receptos/Celgene, Teva, NHLBI, and NICHD; received speaker honoraria from Consortium of MS Centers and Teva; served on the editorial board for <italic>Multiple Sclerosis</italic>, <italic>JASN</italic>, <italic>Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions</italic>; is president of Pythagoras; has consulted for Atara Biotherapeutics, Biogen GmbH, CereSpir Inc., Consortium of MS Centers, Genzyme, Genentech, Innate Therapeutics, Janssen, Klein-Buendel Incorporated, MedImmune, MedDay, Nivalis, Novartis, Opexa Therapeutics, Roche, Savara Inc., Somahlution, Teva, Transparency Life Sciences, and TG Therapeutics; participated in NARCOMS MS Patient Registry; and received research support from NIH/NAID, NIH/National Institute of Neurological Disorders and Stroke, NIH/NHLBI, NIH/NICHD, NIH/NIA, Consortium of MS Centers, US Department of Defense, NIH/NIAMS, NIH/NIDDK, UAB/UCSD, Children's Hospital (Boston), the State of Alabama, and the Myasthenia Gravis Foundation. G. Giovannoni served on the scientific advisory board for Biogen Idec, Five Prime, Genzyme, GQ Pharma, Ironwood, Merck Serono, Novartis, Roche, Sanofi-Aventis, Synthon BV, Teva, Vertex, AbbVie, and Canbex; received speaker honoraria from Biogen Idec, Genzyme, GW Pharma, Merck Serono, Novartis, Roche, and Teva; is editor for <italic>Multiple Sclerosis and Related Disorders</italic>; consulted for Biogen Idec, Five Prime, Genzyme, GW Pharma, Ironwood, Merck Serono, Novartis, Roche, Sanofi-Aventis, Synthon BV, Teva, Vertex, AbbVie, and Canbex; served on the speakers' bureau for Novartis and Teva; and received research support from Genzyme and Merck. B.M.J. Uitdehaag consulted for Novartis, Merck Serono, Biogen Idec, Teva, Sanofi Genzyme, and Roche. JS Wolinsky served on the scientific advisory board for Clene Nanomedicine, Forward Pharma, MedDay, Novartis, Roche/Genentech, and Sanofi/Genzyme; received travel funding and/or speaker honoraria from ACTRIMS, Academic CME, CMSC, PRIME, WebMD, University of Kansas, University of Maryland, ECTRIMS, and ACTRIMS; served on the editorial board for <italic>Multiple Sclerosis Journal</italic>; was editor for <italic>Multiple Sclerosis and Related Disorders</italic>; has consulted for AbbVie, Acetylon, Alkermes, Bayer HealthCare, Celgene, Forward Pharma, EMD Serono, Genzyme, Novartis, Roche, Takeda, and Teva; received research support from NIH; and receives royalties for monoclonal antibodies out-licensed through the University of Texas Health Science Center at Houston to Millipore (Chemicon International) Corporation. M.D. Davis is employed by and holds stock or stock options in Teva Pharmaceutical Industries. J.R. Steinerman served on the data safety monitoring board for NIH; has been employed by Teva Pharmaceutical Industries; consulted for Click Therapeutics; and holds stock or stock options in Teva and Click Therapeutics. V. Knappertz is employed by Teva Pharmaceutical Industries and holds stock or stock options in Teva and Knopp Biosciences. Go to <ext-link ext-link-type="uri" xlink:href="10.1212/NXI.0000000000000358">Neurology.org/nn</ext-link> for full disclosure forms.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">9HPT</term><def><p>9-hole peg test</p></def></def-item><def-item><term id="G2">CDP</term><def><p>confirmed disability progression</p></def></def-item><def-item><term id="G3">DMT</term><def><p>disease-modifying therapy</p></def></def-item><def-item><term id="G4">EDSS</term><def><p>Expanded Disability Status Scale</p></def></def-item><def-item><term id="G5">GA</term><def><p>glatiramer acetate</p></def></def-item><def-item><term id="G6">PPMS</term><def><p>primary progressive MS</p></def></def-item><def-item><term id="G7">T25FW</term><def><p>timed 25-foot walk</p></def></def-item><def-item><term id="G8">UDP</term><def><p>unconfirmed disability progression</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stellmann</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Neuhaus</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lederer</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Daumer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Heesen</surname><given-names>C</given-names></name></person-group>
<article-title>Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review</article-title>. <source>PLoS One</source>
<year>2014</year>;<volume>9</volume>:<fpage>e92761</fpage>.<pub-id pub-id-type="pmid">24651401</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Cutter</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Stys</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Yong</surname><given-names>VW</given-names></name>, <name name-style="western"><surname>Metz</surname><given-names>LM</given-names></name></person-group>
<article-title>Treatment trials in progressive MS—current challenges and future directions</article-title>. <source>Nat Rev Neurol</source>
<year>2013</year>;<volume>9</volume>:<fpage>496</fpage>–<lpage>503</lpage>.<pub-id pub-id-type="pmid">23897406</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS</article-title>. <source>Mult Scler</source>
<year>2012</year>;<volume>18</volume>:<fpage>1534</fpage>–<lpage>1540</lpage>.<pub-id pub-id-type="pmid">22917690</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holland</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Rapp</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kalb</surname><given-names>RC</given-names></name></person-group>
<article-title>Meeting the needs of people with primary progressive multiple sclerosis, their families, and the health-care community</article-title>. <source>Int J MS Care</source>
<year>2011</year>;<volume>13</volume>:<fpage>65</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">24453707</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coetzee</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zaratin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gleason</surname><given-names>TL</given-names></name></person-group>
<article-title>Overcoming barriers in progressive multiple sclerosis research</article-title>. <source>Lancet Neurol</source>
<year>2015</year>;<volume>14</volume>:<fpage>132</fpage>–<lpage>133</lpage>.<pub-id pub-id-type="pmid">25772884</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziemssen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rauer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Stadelmann</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Evaluation of study and patient characteristics of clinical studies in primary progressive multiple sclerosis: a systematic review</article-title>. <source>PLoS One</source>
<year>2015</year>;<volume>10</volume>:<fpage>e0138243</fpage>.<pub-id pub-id-type="pmid">26393519</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ontaneda</surname><given-names>D</given-names></name>, <name name-style="western"><surname>LaRocca</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Coetzee</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rudick</surname><given-names>R</given-names></name></person-group>; <collab>NMSS MSFC Task Force</collab>. <article-title>Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures</article-title>. <source>Mult Scler</source>
<year>2012</year>;<volume>18</volume>:<fpage>1074</fpage>–<lpage>1080</lpage>.<pub-id pub-id-type="pmid">22740488</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosma</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Sonder</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Kragt</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Polman</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Uitdehaag</surname><given-names>BM</given-names></name></person-group>
<article-title>Detecting clinically-relevant changes in progressive multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2015</year>;<volume>21</volume>:<fpage>171</fpage>–<lpage>179</lpage>.<pub-id pub-id-type="pmid">25013153</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Waubant</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cutter</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wolinsky</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Leppert</surname><given-names>D</given-names></name></person-group>
<article-title>Composite end points to assess delay of disability progression by MS treatments</article-title>. <source>Mult Scler</source>
<year>2014</year>;<volume>20</volume>:<fpage>1494</fpage>–<lpage>1501</lpage>.<pub-id pub-id-type="pmid">24675040</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosma</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Kragt</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Brieva</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>The search for responsive clinical endpoints in primary progressive multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2009</year>;<volume>15</volume>:<fpage>715</fpage>–<lpage>720</lpage>.<pub-id pub-id-type="pmid">19383646</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolinsky</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Narayana</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>O'Connor</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial</article-title>. <source>Ann Neurol</source>
<year>2007</year>;<volume>61</volume>:<fpage>14</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">17262850</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwid</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Apatoff</surname><given-names>BR</given-names></name>, <etal>et al</etal></person-group>
<article-title>Are quantitative functional measures more sensitive to worsening MS than traditional measures?</article-title>
<source>Neurology</source>
<year>2000</year>;<volume>55</volume>:<fpage>1901</fpage>–<lpage>1903</lpage>.<pub-id pub-id-type="pmid">11134392</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Korngut</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Patry</surname><given-names>DG</given-names></name>, <etal>et al</etal></person-group>
<article-title>The promise of futility trials in neurological diseases</article-title>. <source>Nat Rev Neurol</source>
<year>2015</year>;<volume>11</volume>:<fpage>300</fpage>–<lpage>305</lpage>.<pub-id pub-id-type="pmid">25776824</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lublin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>
<year>2016</year>;<volume>387</volume>:<fpage>1075</fpage>–<lpage>1084</lpage>.<pub-id pub-id-type="pmid">26827074</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosma</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Kragt</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Knol</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Polman</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Uitdehaag</surname><given-names>BM</given-names></name></person-group>
<article-title>Clinical scales in progressive MS: predicting long-term disability</article-title>. <source>Mult Scler</source>
<year>2012</year>;<volume>18</volume>:<fpage>345</fpage>–<lpage>350</lpage>.<pub-id pub-id-type="pmid">21868487</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Winsen</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Kragt</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Hoogervorst</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Polman</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Uitdehaag</surname><given-names>BM</given-names></name></person-group>
<article-title>Outcome measurement in multiple sclerosis: detection of clinically relevant improvement</article-title>. <source>Mult Scler</source>
<year>2010</year>;<volume>16</volume>:<fpage>604</fpage>–<lpage>610</lpage>.<pub-id pub-id-type="pmid">20086019</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawker</surname><given-names>K</given-names></name>, <name name-style="western"><surname>O'Connor</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial</article-title>. <source>Ann Neurol</source>
<year>2009</year>;<volume>66</volume>:<fpage>460</fpage>–<lpage>471</lpage>.<pub-id pub-id-type="pmid">19847908</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cadavid</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name>, <etal>et al</etal></person-group>
<article-title>The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis</article-title>. <source>Mult Scler</source>
<year>2017</year>;<volume>23</volume>:<fpage>94</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">27003945</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosa</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ghazali</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tanigawa</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Development of a sensitive outcome for economical drug screening for progressive multiple sclerosis treatment</article-title>. <source>Front Neurol</source>
<year>2016</year>;<volume>7</volume>:<fpage>131</fpage>.<pub-id pub-id-type="pmid">27574516</pub-id></mixed-citation></ref></ref-list></back></article>